Erin Delker1, Efrat Aharonovich2, Deborah Hasin3. 1. New York State Psychiatric Institute, New York, NY 10032, United States; San Diego State University/University of California, San Diego Joint Doctoral Program in Public Health (Epidemiology), San Diego, CA 92093, United States. 2. New York State Psychiatric Institute, New York, NY 10032, United States; Columbia University Medical Center, New York, NY 10032, United States. 3. New York State Psychiatric Institute, New York, NY 10032, United States; Columbia University Medical Center, New York, NY 10032, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States. Electronic address: deborah.hasin@gmail.com.
Abstract
BACKGROUND: Substance use can have major consequences among HIV patients. Interviewer- or self-administered modalities are widely used to measure drug use frequency. This often involves Timeline Follow-Back (TLFB) interviewer-administered measures, or self-administered computerized questions assessing similar information via Audio Computer-Assisted Self Interview (A-CASI). Little is known about agreement between these two modalities on drug use frequency in HIV-infected samples. METHODS: Prior to randomization into a trial of brief interventions to reduce drug use, 240 HIV patients completed a baseline A-CASI assessment battery that included questions on drug use frequency, followed by an interviewer-administered TLFB. Each measure generated number of days patients used their primary drug in the prior 30 days. Agreement between TLFB and A-CASI modalities on days using primary drug was determined using intraclass correlation coefficients (ICC). Regression analysis tested the association of patient characteristics with discrepancies between TLFB and A-CASI modalities. RESULTS: Overall agreement was excellent (ICC=.80), with little variation by primary drug, education, race, current drug treatment, binge drinking or years since HIV diagnosis. Gender, ethnicity (Hispanic vs. non-Hispanic) and age predicted differences in days used (p<0.05); the A-CASI modality reflected more days used than TLFB. CONCLUSIONS: Measures of days used primary drug showed high agreement whether assessed by interviewer-administered TLFB or by questions self-administered via the A-CASI modality. Differences by gender, ethnicity and age suggest some caution in using the TLFB, although additional studies are needed. However, findings generally indicate that studies based on one assessment method or the other can be compared with reasonable confidence.
BACKGROUND: Substance use can have major consequences among HIVpatients. Interviewer- or self-administered modalities are widely used to measure drug use frequency. This often involves Timeline Follow-Back (TLFB) interviewer-administered measures, or self-administered computerized questions assessing similar information via Audio Computer-Assisted Self Interview (A-CASI). Little is known about agreement between these two modalities on drug use frequency in HIV-infected samples. METHODS: Prior to randomization into a trial of brief interventions to reduce drug use, 240 HIVpatients completed a baseline A-CASI assessment battery that included questions on drug use frequency, followed by an interviewer-administered TLFB. Each measure generated number of days patients used their primary drug in the prior 30 days. Agreement between TLFB and A-CASI modalities on days using primary drug was determined using intraclass correlation coefficients (ICC). Regression analysis tested the association of patient characteristics with discrepancies between TLFB and A-CASI modalities. RESULTS: Overall agreement was excellent (ICC=.80), with little variation by primary drug, education, race, current drug treatment, binge drinking or years since HIV diagnosis. Gender, ethnicity (Hispanic vs. non-Hispanic) and age predicted differences in days used (p<0.05); the A-CASI modality reflected more days used than TLFB. CONCLUSIONS: Measures of days used primary drug showed high agreement whether assessed by interviewer-administered TLFB or by questions self-administered via the A-CASI modality. Differences by gender, ethnicity and age suggest some caution in using the TLFB, although additional studies are needed. However, findings generally indicate that studies based on one assessment method or the other can be compared with reasonable confidence.
Authors: Jo Ann Y Sacks; Robert E Drake; Valerie F Williams; Steven M Banks; James M Herrell Journal: J Nerv Ment Dis Date: 2003-03 Impact factor: 2.254
Authors: Don C Des Jarlais; Kamyar Arasteh; Theresa Perlis; Holly Hagan; Abu Abdul-Quader; Douglas D Heckathorn; Courtney McKnight; Heidi Bramson; Chris Nemeth; Lucia V Torian; Samuel R Friedman Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Keith A Hermanstyne; David R Bangsberg; Karen Hennessey; Cindy Weinbaum; Judith A Hahn Journal: J Public Health (Oxf) Date: 2012-03-26 Impact factor: 2.341
Authors: Sharon Levy; Lon Sherritt; Sion Kim Harris; Elizabeth C Gates; David W Holder; John W Kulig; John R Knight Journal: Alcohol Clin Exp Res Date: 2004-08 Impact factor: 3.455
Authors: Jennifer McNeely; Shiela M Strauss; Shana Wright; John Rotrosen; Rubina Khan; Joshua D Lee; Marc N Gourevitch Journal: J Subst Abuse Treat Date: 2014-02-10
Authors: Keith J Horvath; Sara Lammert; Sara LeGrand; Kathryn E Muessig; José A Bauermeister Journal: Curr Opin HIV AIDS Date: 2017-09 Impact factor: 4.283
Authors: Erica N Grodin; Lara A Ray; James MacKillop; Aaron C Lim; Mitchell P Karno Journal: Alcohol Clin Exp Res Date: 2019-01-20 Impact factor: 3.455
Authors: Eric Abella Roth; Zishan Cui; Heather L Armstrong; Ashleigh J Rich; Nathan J Lachowsky; Paul Sereda; Kiffer G Card; Nic Bacani; David Moore; Robert Hogg Journal: J Bisex Date: 2021-10-14
Authors: Deborah S Hasin; Efrat Aharonovich; Barry S Zingman; Malka Stohl; Claire Walsh; Jennifer C Elliott; David S Fink; Justin Knox; Sean Durant; Raquel Menchaca; Anjali Sharma Journal: J Subst Abuse Treat Date: 2022-01-31